



University of Colorado
Anschutz Medical Campus
School of Medicine

Curriculum vitae

Katharina Hopp, Ph.D.
katharina.hopp@cuanschutz.edu

Current Position

Assistant Professor of Medicine
Division of Renal Disease and Hypertension
University of Colorado, Denver, Anschutz Medical Campus
PKD Program

Address

University of Colorado
Anschutz Medical Campus
P15 Room 7400A, Mail Stop C281
12700 East 19th Ave
Aurora, CO 80045
Phone (office): 303-724-1858
Phone (lab): 303-724-4822
Fax: 303-724-4868
e-mail: katharina.hopp@cuanschutz.edu

Education

2004-2008	Brescia University, Owensboro KY	B.S. Biology, Chemistry
2006	University of Louisville, Louisville KY	Summer Research Internship Dr. Steven R. Ellis
2007	Mayo Clinic, Rochester MN	Summer Research Internship Dr. Peter C. Harris
2008-2012	Mayo Clinic, Rochester MN	Ph.D. Biochemistry and Molecular Biology
2012-2015	Mayo Clinic, Rochester MN	Post-doctoral Training, Mayo Clinic Translational Polycystic Kidney Disease Center, Dr. Peter C. Harris
2013-present	University of Minnesota, Minneapolis MN	M.S. Biomedical Informatics and Computational Biology

Academic Appointments

2013-2016	Mayo Clinic, Rochester MN	Co-director, Mayo Clinic Translational PKD Center, Model Systems Core
2013-2015	Mayo Clinic, Rochester MN	Research Fellow
2015	Mayo Clinic, Rochester MN	Senior Research Fellow
2015-2017	University of Colorado Denver, Anschutz Medical Campus CO	Instructor, Department of Medicine
2015-2019	Mayo Clinic, Rochester MN	Research Collaborator
2017-present	University of Colorado, Denver, Anschutz Medical Campus CO	Assistant Professor, Department of Medicine
2017-2020	Mayo Clinic, Rochester MN, Mayo Clinic Translational Polycystic Kidney Disease Center	External Faculty
2018-present	University of Maryland, Baltimore, MD, Baltimore Polycystic Kidney Disease Research and Clinical Core Center	External Faculty
2020-present	University of Colorado, Denver, Anschutz Medical Campus CO	Director, PKD Program, Murine Pre-clinical core

Administrative Appointments

2010-2011	Mayo Clinic, Rochester MN, Mayo Clinic Graduate School	Organizer, Mayo Graduate School Association – Biochemistry and Molecular Biology Symposium
2012-2014	Mayo Clinic, Rochester MN, Division of Nephrology and Hypertension	Co-manager, “Orientation, Safety & Security Focus Group”
2013-2014	Mayo Clinic, Rochester MN, Postdoctoral Association	Steering Committee Member, Mayo Clinic Young Investigator Research Symposium
2013-2014	Mayo Clinic, Rochester MN, Postdoctoral Association	Vice-president, Mayo Research Fellows Association
2013-2015	Mayo Clinic, Rochester MN, Rare Kidney Stone Consortium	Genetics Advisor, Primary Hyperoxaluria Center
2013-2016	Mayo Clinic, Rochester MN, Mayo Clinic Translational Polycystic Kidney Disease Center	Consultant, Molecular Genetics and Proteomics Core, Mayo Translation PKD Center
2016-present	University of Colorado Denver, Anschutz Medical Campus, PKD Program	Organizer, PKD Program Bi-weekly Update Series

2016-present	University of Colorado Denver, Anschutz Medical Campus, PKD Program	Organizer, Career Development Workshop Series
--------------	---	---

Honors, Special Recognitions, and Awards

2006	Kentucky Academy of Science	Undergraduate Research Competition, Cellular and Molecular Biology, 1 st Place
2007	Kentucky Academy of Science	Undergraduate Research Competition, Cellular and Molecular Biology, 3 rd Place
2008	Brescia University, Owensboro KY	B.S. Summa Cum Laude
2011	Mayo Clinic, Rochester MN, Mayo Clinic Graduate School	Travel Award
2012	Mayo Clinic, Rochester MN, Mayo Clinic Graduate School	Distinguished Poster Award, Division: Graduate Student, Young Investigator Research Symposium
2014	Oxalosis and Hyperoxaluria Foundation	Travel Award
2014	Mayo Clinic, Rochester MN, Mayo Clinic Translational Polycystic Kidney Disease Center	Mayo Clinic Department of Medicine, Outstanding Research Fellow Award
2014	Mayo Clinic, Rochester MN, Mayo Clinic Translational Polycystic Kidney Disease Center	Mayo Research Fellow's Day, Poster Presentation Award
2018	Polycystic Kidney Disease Foundation	Dr. Vincent H. Gattone Research Award

Professional Memberships

2010-present	American Society of Human Genetics
2012-present	American Society of Nephrology
2012-present	American Heart Association
2017-present	International Society of Nephrology

Committees/Service Responsibilities

2015-present	Colorado Clinical & Translational Science Institute	Committee member, National
2015-present	PKD Focus Group	Organizer, University of Colorado, Denver
2017-present	Consortium for Fibrosis Research & Translation	Committee member, University of Colorado, Denver

2018-present Division of Renal Diseases and Hypertension bi-annual research workshop

Chair, University of Colorado, Denver

Inventions, intellectual property, and patents held or pending

2012-present Invention, Mayo Clinic Ventures, *Pkd1* R3277C Mouse Model, Mayo Technology Case #2012-144

2019-present Invention, Mayo Clinic Ventures, Digenic Mouse and Rat Models Mimicking Early Onset ARPKD, Mayo Technology Case #2019-331

Review and Referee Work

Journal Reviewer (ad hoc)

2013-present Am J Nephrol
2013-present Am J Path
2013-present Am J Physiol - Renal Physiol
2013-present Anal Chem
2013-present Dev Dyn
2013-present J Am Soc Nephrol
2013-present J Nephrol
2013-present J Mol Diagn
2013-present Kidney Int
2014-present BMC Med Genet
2014-present Hum Mol Gen
2014-present Proc Natl Acad Sci USA
2014-present Transplant
2016-present Genet Test Mol Biomarkers
2018-present Kidney Int Rep
2018-present Sci Rep
2019-present Kidney 360
2020-present Cells
2020-present Expert Opin Ther Targets
2020-present JoVE
2020-present Cancers
2020-present Genes
2021-present Clin Sci

Grant Reviewer

2013	Pilot & Feasibility Grants, Mayo Clinic Rare Kidney Stone Consortium
2017	NIH, NIDDK (invited)
2019	Colorado Clinical and Translational Science Institute Novel Methods Development Program
2019	DoD, PRMRP (invited)
2020	Polycystic Kidney Disease Foundation Research Grants
2020	DoD, PRMRP (invited)
2021	Colorado Clinical and Translational Science Institute Translational Methods Grant Program

Other Reviewer/Referee Work

2013, 2014	Judge, Mayo Graduate School Student Symposium
2017	Moderator, ASN Kidney Week
2018	Judge, University of Colorado Denver, Anschutz Medical Campus, Postdoctoral Association Research Day
2018	Judge, University of Colorado Denver, Anschutz Medical Campus, Pharmacology Student and Post-Doc Research Day
2018	Judge, University of Colorado Denver, Anschutz Medical Campus, Annual Student Research Forum
2019	Abstract Reviewer, ASN Kidney Week
2019	Moderator, ASN Kidney Week
2019	Judge, University of Colorado Denver, Anschutz Medical Campus, Annual Student Research Forum
2021	FASEB Catalyst Conference, <i>In Vivo</i> Models of Relevance to PKD Research, Discussion Panel Chair

Invited Lectures/Faculty

International/National

1.	2013	GoldenHelix workshop/webinar	"Using GoldenHelix SVS to Elucidate the Genetics of Kidney Disease."
2.	2015	University of Kansas Biochemistry Department and Kidney Institute	"Genic and allelic modulators of Autosomal Dominant Polycystic Kidney Disease severity."
3.	2017	FASEB Polycystic Kidney Disease: Challenges, Differing Viewpoints and Ways Forward	"The role of the adaptive immune system in ADPKD."

- | | | | |
|----|------|---|---|
| 4. | 2018 | University of Alabama Birmingham, Cell, Developmental and Integrative Biology Program & Nephrology Research and Training Center | “Thinking beyond the renal epithelium: The role of the cystic microenvironment in Autosomal Dominant Polycystic Kidney Disease progression.”; “Genetic & Immune Modulators of Autosomal Dominant Polycystic Kidney Disease Severity.” |
| 5. | 2019 | University of Maryland, Baltimore Polycystic Kidney Disease Research and Clinical Core Center | “Targeting the Cystic Microenvironment in Polycystic Kidney Disease” |
| 6. | 2020 | ASN Kidney Week Reimagined | “The role of T cell in cyst progression” |
| 7. | 2021 | FASEB Catalyst Conference, <i>In Vivo</i> Models of Relevance to PKD Research | “Overview of Murine PKD Models Used for Translational Research” |
| 8. | 2021 | Otsuka, Educational Seminar | “The Future of PKD Research” |

Regional/Local

- | | | | |
|----|------|---|---|
| 1. | 2010 | Medical Genetics Research Forum, Mayo Clinic Rochester, MN | “Genetic complexity of Polycystic Kidney Disease.” |
| 2. | 2011 | NextGen Sequencing Working Group Meeting, Mayo Clinic Rochester, MN | “Characterization of oligogenic inheritance in Meckel Syndrome using targeted exon-enriched next-generation sequencing.” |
| 3. | 2011 | Mayo Translation Polycystic Kidney Disease Center Retreat/Mini-Symposium | “The <i>Pkd1</i> hypomorphic allele, R3277C, modifies the <i>Pkd1</i> ^{+/-} phenotype to early onset disease, suggesting a dose dependent pathogenesis of Autosomal Dominant Polycystic Kidney Disease.” |
| 4. | 2014 | Mayo Translation Polycystic Kidney Disease Center Retreat/Mini-Symposium | “Genetic characterization of ARPKD-like and Meckel syndrome pedigrees using a next-generation sequencing ciliopathy gene panel.” |
| 5. | 2014 | European Site Visit – Mayo Clinic Translational Polycystic Kidney Disease Center | “Next-generation sequencing of ciliopathy screening.”; “Overview of the Rodent Model Systems Core (Mayo Translational PKD Center).” |
| 6. | 2014 | Medical Genetics Research Forum, Mayo Clinic Rochester, MN | “Using next-generation sequencing for enhanced diagnostics in ciliopathies.” |
| 7. | 2017 | Department of Medicine Research and Innovation Conference, University of Colorado Denver, Anschutz Medical Campus | “Genetic and microenvironmental modulators of Autosomal Dominant Polycystic Kidney Disease severity.” |

Teaching Records

2009-2010	Mayo Clinic, Rochester MN, Mayo Clinic Graduate School	Track Representative, Biochemistry and Molecular Biology, Mayo Graduate School Association
2011	Mayo Clinic, Rochester MN, Mayo Clinic Graduate School	Teaching Assistant, Core6500: Biochemistry and Molecular Biology Journal Club
2011-2012	Mayo Clinic, Rochester MN, Mayo Clinic Graduate School	Teaching Assistant, Core5200: Biochemistry and Molecular Biology Works in Progress
2012	Mayo Clinic, Rochester MN, Mayo Clinic Graduate School	Lecturer, Core6400: Molecular Genetics
2012	Mayo Clinic, Rochester MN, Mayo Clinic Graduate School	Teaching Assistant, Core6400: Molecular Genetics
2013-2014	Mayo Clinic, Rochester MN, Mayo Clinic Translational Polycystic Kidney Disease Center	Lecturer, Core6510: Molecular Mechanisms of Human Disease
2021	University of Colorado Denver, Anschutz Medical Campus, Graduate School, Integrated Physiology Program	Lecturer, IPHY7800: Comprehensive Physiology – Renal Physiology
2021	University of Colorado Denver, Anschutz Medical Campus, Graduate School, Integrated Physiology Program	Lecturer, IPHY7800: Comprehensive Physiology – Renal Diseases

Trainees/Mentees

Date	Name	Position	Project Title	Current Status
2012-2013	Tamara Restrepo	Post-baccalaureate Student	Analysis of the role of Mucin (MUC) 1 in Medullary Cystic Kidney Disease Type 1 (MDCK1)	Molecular Supervisor, Department of Pathology, Boston Children's Hospital, Boston MA
2013	Kalen Petersen	Summer Undergraduate Research Fellow	Analysis of the Dynamic Pattern of Cyst Development in the Hypomorphic	PhD Candidate, Chemical and Physical Biology Program, Vanderbilt School of Medicine, Nashville TN
2014	Kari Mattison	Summer Undergraduate Research Fellow	Dent Disease: Deep intronic/UTR mutation analysis and mutation database development	PhD Candidate, Emory University, Laney Graduate School, Genetics and Molecular Biology Graduate Program, Atlanta GA

2014	Michelle Hulke	Summer Undergraduate Research Fellow	Simplified specific enrichment of the <i>PKD1</i> coding region to simplify screens by next-generation sequencing approaches	PhD Candidate, The Graduate Field of Genetics, Genomics and Development, Cornell University Ithaca NY
2014-2015	Binu (Paul) Porath	Postdoctoral Fellow	Using next-generation sequencing to resolve mutation negative Autosomal Dominant Polycystic Kidney Disease patients	Laboratory Genetics and Genomics Fellow, Children's Mercy Hospital, Kansas City MO
2015-2018	Emily Kleczko	Postdoctoral Fellow	Investigating the role of the adaptive immune system in Polycystic Kidney Disease	Instructor, Division of Renal Diseases and Hypertension, University of Colorado, Denver, Anschutz Medical Campus, Denver CO
2015-2018	Kenneth Marsh	Professional Research Assistant	Lab Manager	Medical Student, New York Medical College, Valhalla, NY
2017-2018	Logan Tyler	PhD Student	Understanding the role of CD8 ⁺ T-cells in Polycystic Kidney Disease Progression	PhD Candidate, Pharmacology Graduate Program, University of Colorado, Denver, Anschutz Medical Campus, Denver CO
2018-present	Dustin Nguyen	Professional Research Assistant	Lab Manager	Professional Research Assistant, Division of Renal Diseases and Hypertension & Master Student, Biomedical Sciences & Biotechnology Program, University of Colorado, Denver, Anschutz Medical Campus, Denver CO
2019	Amy Li	Internal Medicine Resident Research Elective	T cell and renal epithelial cell co-culture	Department of Medicine, Internal Medicine, Resident, University of Colorado, Denver, Anschutz Medical Campus, Denver CO
2020-present	Amber Johnson	NIDDK T32 Postdoctoral Fellow	Injury-mediated T cell function in PKD	NIDDK T32 Postdoctoral Fellow, University of Colorado, Denver, Anschutz Medical Campus, Denver CO
2020-present	Nidhi Dwivedi	Instructor	The role of complement in PKD progression	Instructor, Department of Medicine, Division of Renal Diseases and Hypertension, University of Colorado, Denver, Anschutz Medical Campus, Denver CO

2021-present	Zachary Snyder	Professional Research Assistant	PKD Program Pre-clinical core manager	PKD Program Pre-clinical core manager, Division of Renal Diseases and Hypertension, University of Colorado, Denver, Anschutz Medical Campus, Denver CO
--------------	----------------	---------------------------------	---------------------------------------	--

Grant Support

Active

R01 DK59597 (Harris, PI) – Hopp (Consultant) NIH/NIDDK Genetic analysis of the Ciliopathies ARPKD and Meckel Syndrome	02/01/18 – 01/31/23 \$289,371/year	0 CME
---	---------------------------------------	-------

K01DK114164 (Hopp, PI) NIH/NIDDK Defining the functional role of T cells in Autosomal Dominant Polycystic Kidney Disease pathology.	07/01/18 – 06/30/23 \$150,000/year	10 CME
---	---------------------------------------	--------

K01 DK114164-03S1 (Hopp, PI) NIH/NIDDK K01DK114164 Supplement, NIH Notice of Special Interest NOT-OD-20-054	08/01/20 – 07/31/21 \$35,857/year	0 CME
---	--------------------------------------	-------

R03DK129414 (Hopp, PI) NIH/NIDDK Complement as a modulator of immunosuppression and progression in Polycystic Kidney Disease	07/01/21 – 06/31/23	2CME
--	---------------------	------

PKD Foundation (Hopp, PI) Research Grant Caloric restriction in PKD: Mechanisms mediating efficacy and impact on immune cell function.	07/01/21 – 06/31/23	
--	---------------------	--

Completed

P30 DK090728 (Torres, PI) – Hopp (Consultant) NIH/NIDDK Mayo Translational PKD Center (MTPC)	09/30/10 – 06/30/15	
--	---------------------	--

11PRE5250020 (Hopp, PI) AHA Predoctoral Fellowship Molecular analysis of a dosage dependent pathobiology in autosomal dominant polycystic kidney disease (ADPKD)	01/01/11 – 12/31/12	
--	---------------------	--

Ben J. Lipps Research Fellowship (Hopp, PI) American Society of Nephrology Research Fellowship Identification of modifier genes that cause early-onset autosomal dominant polycystic kidney disease using next-generation sequencing	07/01/13 – 06/30/15	
--	---------------------	--

CIM Clinomics Program (Hopp/Harris, Co-PI) Mayo Center for Individualized Medicine Identification of novel Primary Hyperoxaluria genes by whole exome sequencing of mutation negative pedigrees.	08/01/13 – 07/31/14	
--	---------------------	--

R01 DK58816 (Harris, PI) – Hopp (Consultant) NIH/NIDDK ADPKD: Disease Spectrum & Genotype-Phenotype	06/01/14 – 05/31/19
U54DK083908 (Milliner, PI) – Hopp (Consultant) NIH/NIDDK Hereditary Causes of Nephrolithiasis and Kidney Failure	07/01/14 – 06/30/19
P30 DK090728 (Torres, PI) – Hopp (Consultant) NIH/NIDDK Mayo Translational PKD Center (MTPC)	07/01/15 – 06/30/20
Pilot & Feasibility Grant (Nemenoff, PI) – Hopp (Co-I) University of Colorado Denver Center for Fibrosis Research and Translation Role of immune cells in mediating Fibrosis in ADPKD	07/01/16 – 06/30/17
Pilot & Feasibility Grant (Hopp, PI) Mayo Translational PKD Center A functional genomics screen to identify somatic modifiers/drivers of ADPKD cystogenesis	10/01/16 – 06/30/18
PRMRP W81XWH-17-1-0107 (Hopp, PI) Department of Defense Application of the Sleeping Beauty Transposon System to Identify Regulatory Genes Driving ADPKD Cystogenesis and Phenotypic Heterogeneity	07/01/17 – 12/31/19
Pilot & Feasibility Grant (Hopp, PI) University of Colorado, GI and Liver Innate Immune Program Investigating the role of complement in polycystic liver disease	11/15/17 – 11/14/19
Pilot & Feasibility Grant (Hopp, PI) 07/01/18 – 06/30/20 Baltimore PKD Research and Clinical Core Center Evaluating kynurenine pathway catabolites as biomarker for ADPKD progression and driver of a pro cystogenic microenvironment	
PKD Foundation (Hopp, PI) Research Grant Understanding the role of CD8+ T cells in halting renal cystogenesis	07/01/18 – 12/31/20

Peer Reviewed Publications

1. Rossetti S, Kubly VJ, Consugar MB, **Hopp K**, Roy S, Horsley SW, Chauveau D, Rees L, Barratt TM, van't Hoff WG, Niaudet WP, Torres VE, Harris PC. Incompletely penetrant *PKD1* alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. *Kidney Int.* 2009 Apr, 75(8):848-55. PMID: 19165178
2. Vujic M, Heyer CM, Ars E, **Hopp K**, Markoff A, Orndal C, Rudenhed B, Nasr SH, Torres VE, Torra R, Bogdanova N, Harris PC. Incompletely penetrant *PKD1* alleles mimic the renal manifestations of ARPKD. *J Am Soc Nephrol.* 2010 Jul, 21(7):1097-1102. PMID: 20558538
3. **Hopp K**, Heyer CM, Hommerding CJ, Henke SA, Sundsbak JL, Patel S, Patel P, Consugar MB, Czarnecki P, Gliem TJ, Torres VE, Rossetti S, Harris PC. *B9D1* is revealed as a novel Meckel syndrome (MKS) gene by targeted exon-enriched next-generation sequencing and deletion analysis. *Hum Mol Genet.* 2011 Jul, 2(13):2524-34. PMID: 21493627

4. Rossetti S, **Hopp K**, Sikkink RA, Sundsbak JL, Lee YK, Kubly V, Eckloff BW, Ward CJ, Winearls C, Torres VE, Harris PC. Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. *J Am Soc Nephrol*. 2012 May, 23(5):915-33. PMID: 22383692
5. **Hopp K**, Ward CJ, Hommerding CJ, Nasr SH, Tuan H, Gainullin VG, Rossetti S, Torres VE, Harris PC. Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. *J Clin Invest*. 2012 Nov 1, 122(11):4257-73. PMID: 23064367
6. Paul BM, Consugar MB, Lee MR, Sundsbak JL, Heyer CM, Rossetti S, Kubly VJ, **Hopp K**, Torres VE, Coto E, Clementi M, Bogdanova N, de Almeida E, Bichet DG, Harris PC. Evidence of a third ADPKD locus is not supported by the analysis of described PKD3 families. *Kidney Int*. 2014 Feb, 85(2):383-92. PMID: 23760289
7. **Hopp K**, Hommerding CJ, Wang X, Ye H, Harris PC, Torres VE. Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model. *J Am Soc Nephrol*. 2015 Jan, 26(1):39-47. PMID: 24994926
8. Gainullin VG, **Hopp K**, Ward CJ, Hommerding CJ, Harris PC. Polycystin-1 maturation requires polycystin-2 in a dose dependent manner. *J Clin Invest*. 2015 Feb, 125(2):607-20. PMID 25574838
9. **Hopp K***, Wang X*, Ye Hong, Irazabal, MV, Harris PC, Torres VE. Effects of hydration in rats and mice with polycystic kidney disease. *Am J Physiol - Renal Physiol*. 2015 Feb, 308(3):F261-6. PMID: 25503729
*These authors contributed equally to the work.
10. **Hopp K***, Cogal AG*, Bergstralh EJ, Seide BM, Olson JB, Meek AM, Lieske JC, Milliner DS, Harris PC. Phenotype-genotype correlations and estimated carrier frequency of primary hyperoxaluria. *J Am Nephrol*. 2015. Oct;26(10):2559-70 PMID: 25644115
*These authors contributed equally to the work.
11. Kline, TL, Irazabal MV, Ebrahimi B, **Hopp K**, Udoji KN, Warner JD, Korfiatis P, Mishra PK, Macura SI, Venkatesh SK, Lerman LO, Harris PC, Torres VE, King BF, Erikson BJ. Utilizing magnetization transfer imaging to investigate tissue remodeling in a murine model of autosomal dominant polycystic kidney disease. *Magnet Reson Med*. 2015. May 13. PMID: 25974140
12. Ye H, Wang X, Sussman CR, **Hopp K**, Irazabal MV, Bakeberg JL, LaRiviere WB, Manganiello VC, Vorhees CV, Zhao H, Harris PC, van Deursen J, Ward CJ, Torres VE. Modulation of Polycystic Kidney Disease Severity by Phosphodiesterase 1 and 3 Subfamilies. *J Am Soc Nephrol*. 2015 Sep 15. PMID: 26374610.
13. Warner G, Hein KZ, Nin V, Edwards M, Chini CC, **Hopp K**, Harris PC, Torres VE, Chini EN. Food Restriction Ameliorates the Development of Polycystic Kidney Disease. *J Am Soc Nephrol*. 2015 Nov 4. PMID: 26538633.
14. Heyer CM, Sundsbak JL, Abebe KZ, Chapman AB, Torres VE, Grantham JJ, Bae KT, Schrier RW, Perrone RD, Braun WE, Steinman TI, Mrug M, Yu AS, Brosnahan G, **Hopp K**, Irazabal MV, Bennett WM, Flessner MF, Moore CG, Landsittel D, Harris PC. Predicted Mutation Strength of Nontruncating *PKD1* Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. *J Am Soc Nephrol*. 2016 Jan 28. PMID: 26823553.

15. Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, Heyer CM, **Hopp K**, Edwards ME, Madsen CD, Mauritz SR, Banks CJ, Baheti S, Reddy B, Herrero JI, Bañales JM, Hogan MC, Tasic V, Watnick TJ, Chapman AB, Vigneau C, Lavainne F, Audrézet MP, Ferec C, Le Meur Y, Torres VE, Harris PC. Mutations in GANAB, Encoding the Glucosidase II α Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. *Am J Hum Genet.* 2016 Jun 2;98(6):1193-207. PMID: 27259053.
16. Cornec-Le Gall E, Olson RJ, Besse W, Heyer CM, Gainullin VG, Smith JM, Audrézet MP, **Hopp K**, Porath B, Shi B, Baheti S, Senum SR, Arroyo J, Madsen CD, Férec C, Joly D, Jouret F, Fikri-Benbrahim O, Charasse C, Coulibaly JM, Yu AS, Khalili K, Pei Y, Somlo S, Le Meur Y, Torres VE; Genkyst Study Group; HALT Progression of Polycystic Kidney Disease Group; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease, Harris PC. Monoallelic mutations to DNAJB11 cause atypical autosomal dominant polycystic kidney disease. *Am J Hum Genet.* 2018 May 3;102(5):832-844. PMID 29706351
17. Boczek NJ, **Hopp K**, Benoit L, Kraft D, Cousin MA, Blackburn PR, Madsen CD, Oliver GR, Nair AA, Na J, Bianchi DW, Beek G, Harris PC, Pichurin P, Klee EW. Characterization of three ciliopathy pedigrees expands the phenotype associated with biallelic C2CD3 variants. *Eur J Hum Genet.* 2018 Dec;26(12):1797-1809. PMID: 30097616
18. Kleczko EK, Marsh KH, Tyler LC, Furgeson SB, Bullock BL, Altmann CJ, Miyazaki B, Gitomer BY, Harris PC, Weiser-Evans MCM, Chonchol MB, Clambey ET, Nemenoff RA*, **Hopp K***. CD8⁺ T-cells Modulate Autosomal Dominant Polycystic Kidney Disease Progression. *Kidney Int.* 2018 Dec;94(6):1127-1140. PMID: 30249252
*Co-corresponding authors.
19. Montford JR, Bauer C, Dobrinskikh E, **Hopp K**, Levi M, Weiser-Evans MC, Nemenoff RA, Furgeson SB. Inhibition of 5-Lipoxygenase decreases renal fibrosis and progression of chronic kidney disease. *Am J Physiol Renal Physiol.* 2019 Apr 1;316(4):F732-F742.PMID: 30649890
20. Holditch SJ, Brown CN, Atwood DJ, Lombardi AM, Nguyen KN, Toll HW, **Hopp K**, Edelstein CL. A study of sirolimus and an mTOR kinase inhibitor (TORKi) in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease (ADPKD). *Am J Physiol Renal Physiol.* 2019 Jul 1;317(1):F187-F196. PMID: 31042058
21. Bullock BL, Kimball AK, Poczobutt JM, Neuwelt AJ, Li HY, Johnson AM, Kwak JW, Kleczko EK, Kaspar RE, Wagner EK, **Hopp K**, Schenk EL, Weiser-Evans MC, Clambey ET, Nemenoff RA. Tumor-intrinsic response to IFN γ shapes the tumor microenvironment and anti-PD-1 response in NSCLC. *Life Sci Alliance.* 2019 May 27;2(3). PMID: 31133614
22. Olson RJ, **Hopp K**, Wells H, Smith JM, Furtado J, Constans MM, Escobar DL, Geurts AM, Torres VE, Harris PC. Synergistic genetic interactions between *Pkhd1* and *pkd1* result in an ARPKD-like phenotype in murine models. *J Am Soc Nephrol.* 2019. Nov;30(11):2113-2127. PMID: 31427367
23. Gewin LS, Summers ME, Harral JW, Gaskill CF, Khodo SN, Neelisetty S, Sullivan TM, **Hopp K**, Reese JJ, Klemm DJ, Kon V, Ess KC, Shi W, Majka SM. Inactivation of *Tsc2* in *Abcg2* lineage-derived cells drives the appearance of polycystic lesions and fibrosis in the adult kidney. *Am J Physiol Renal Physiol.* 2019. Nov 1;317(5):F1201-F1210. PMID: 31461347
24. Holditch SJ, Brown CN, Atwood DJ, Pokhrel D, Brown SE, Lombardi AM, Nguyen KN, Hill RC, Lanaspá M, **Hopp K**, Weiser-Evans MCM, Edelstein CL. The consequence of increased 4E-BP1 in Polycystic Kidney Disease. *Hum Mol Genet.* 2019. Dec 15;28(24):4132-4147. PMID: 31646342

25. **Hopp K**, Cornec-Le Gall E, Senum SR, Te Paske IBAW, Raj S, Lavu S, Baheti S, Edwards ME, Madsen CD, Heyer CM, Ong ACM, Bae KT, Fatica R, Steinman TI, Chapman AB, Gitomer B, Perrone RD, Rahbari-Oskoui FF, Torres VE; HALT Progression of Polycystic Kidney Disease Group, the ADPKD Modifier Study, Harris PC. Detection and characterization of mosaicism in Autosomal Dominant Polycystic Kidney Disease. *Kidney Int.* 2020 Feb;97(2):370-382. PMID: 31874800
26. Johnson AM, Bullock BL, Neuwelt AJ, Poczobutt JM, Kaspar RE, Li HY, Kwak JW, **Hopp K**, Weiser-Evans MCM, Heasley LE, Schenk EL, Clambey ET, Nemenoff RA. Cancer Cell-Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Anti-PD-1 Therapy in Lung Adenocarcinoma. *J Immunol.* 2020 Apr 15;204(8):2295-2307. PMID: 32179637.
27. Atwood DJ, Pokhrel D, Brown CN, Holditch SJ, Bachu DM, Thorburn A, **Hopp K**, Edelstein CL. Increased mTOR and suppressed autophagic flux in the heart of a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease. *Cell Signal.* 2020 Oct;74:109730. doi: 10.1016/j.cellsig.2020.109730. Epub 2020 Jul 28. PMID: 32730856.
28. Atwood DJ, Brown CN, Holditch SJ, Pokhrel D, Thorburn A, **Hopp K**, Edelstein CL. The effect of trehalose on autophagy-related proteins and cyst growth in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease. *Cell Signal.* 2020 Nov;75:109760. doi: 10.1016/j.cellsig.2020.109760. Epub 2020 Aug 29. PMID: 32866627
29. Baliga MM, Klawitter J, Christians U, **Hopp K**, Chonchol M, Gitomer BY, Cadnapaphornchai MA, Klawitter J. Metabolic profiling in children and young adults with autosomal dominant polycystic kidney disease. *Sci Rep.* 2021 Mar 23;11(1):6629. doi: 10.1038/s41598-021-84609-8. PMID: 3375823
30. Arroyo J, Escobar-Zarate D, Wells HH, Constans MM, Thao K, Smith JM, Sieben CJ, Martell MR, Kline TL, Irazabal MV, Torres TE, **Hopp K***, Harris PC*. Genetic background significantly impacts the severity of renal cystic disease in the Pkd1RC/RC model of ADPKD. *Kidney Int.* 2021 Mar 8:S0085-2538(21)00259-3. doi: 10.1016/j.kint.2021.01.028. Online ahead of print. PMID: 33705824
*Co-corresponding authors.

Note: **Hopp K** has currently under review 3 publications as corresponding authors, and 2 publications as co-author.

Book Chapters/Editorial/Digital Education Publications

1. **Hopp K**, Harris PC. Molecular analysis of a dosage dependent pathobiology in autosomal dominant polycystic kidney disease (ADPKD). Department of Biochemistry and Molecular Biology - Annual Report. 2010.
2. Harris PC, **Hopp K**. Editorial: The mutation, a key determinant of phenotype in ADPKD. *J Am Soc Nephrol.* 2013 May, 24(6):868-70. PMID: 2368735
3. American Society of Nephrology Workforce Committee, "Career Options in Nephrology", "Rewards of a Nephrology Career", "Qualities of a Nephrologist". ASNKidneyTube. YouTube Video. 2014 Jan 31.
4. Lieske JC, Milliner DS, Beara-Lasic L, Harris PC, **Hopp K**, Cogal AG, Mattison K. Dent Disease. 2012 Aug 9 [Updated 2014 Sep 25]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. *GeneReviews*® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. <http://www.ncbi.nlm.nih.gov/books/NBK99494/>

5. **Hopp K.** Commentary: Improving HNF1 β mutation detection rates: Can a weighted score of clinical and familial characteristics help? *Kidney Int.* 2014 Nov, 86(5):882-4. PMID: 25360493
6. Holditch SJ, Nemenoff RA, **Hopp K.** Polycystic Kidney Disease: Chapter 10 Rodent Autosomal Dominant Polycystic Kidney Disease Models. *CRC Press.* 2019. Nov 7
7. Nemenoff RA, Kleczko EK, **Hopp K.** Commentary: Renal double negative T cells: unconventional cells in search of a function. *Ann Transl Med.* 2019 Dec;7(Suppl 8):S342. doi: 10.21037/atm.2019.09.107. PMID: 32016060
8. Nowak KL, **Hopp K.** Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Evidence and Therapeutic Potential. *Clin J Am Soc Nephrol.* 2020 Feb 21:CJN.13291019. doi: 10.2215/CJN.13291019. Online ahead of print. PMID: 32086281
9. Zimmerman KA*, **Hopp K***, Mrug M. Role of chemokines, innate and adaptive immunity. *Cell Signal.* 2020 Apr 20:109647. doi: 10.1016/j.cellsig.2020.109647. PubMed PMID: 32325183. *Co-first authors.

National/International Scientific Presentations/Abstracts

Competitive Oral Abstracts

1. **Hopp K,** Marvin J, Ellis S. RPL46A does not compensate the growth defect caused by deletion of SDO1, a yeast homolog of the human Shwachman-Diamond Syndrome gene. Kentucky Academy of Science (KAS). 2005.
2. **Hopp K,** Marvin J, Harris PC. Analysis of atypical splicing in the ADPKD genes. Kentucky Academy of Science (KAS). 2007
3. Rossetti S, Sundsbak JL, Eckloff BW, Sikkink RA, Lee YK, **Hopp K,** Kubly V, Winearls C, Wieben ED, Torres VE, Harris PC. Deep sequencing of the PKD1 and PKD2 genes in autosomal dominant polycystic kidney disease (ADPKD) by indexed and multiplexed next-generation sequencing (NGS). FASEB 2011.
4. **Hopp K,** Ward CJ, Rossetti S, Sundsbak JL, Torres VE, Harris PC. Characterization of clinical PKD1 variants validates the dosage-dependence of Autosomal Dominant Polycystic Kidney Disease. Mayo Graduate School Student Symposium. 2012
5. **Hopp K,** Rossetti S, Irazabal MV, Paul BM, Sundsbak JL, Heyer CM, Torres VE, Harris PC. Identification of mosaic mutations in mild, mutation negative ADPKD patients using next-generation sequencing [Abstract]. *J Am Soc Nephrol.* 2013 24: 58A.
6. Gainullin VG, **Hopp K,** Ward CJ, Olson RJ, Hommerding CJ, Harris PC. Chaperone-like function of polycystin-2 governs polycystin-1 maturation and modifies PKD severity. FASEB 2014
7. **Hopp K,** Cogal AG, Bergstrahl EJ, Seide BM, Olson JB, Meek AM, Milliner DS, Harris PC. Phenotype-genotype correlations in primary hyperoxaluria. 11th International Primary Hyperoxaluria Workshop. 2014.
8. **Hopp K,** Cogal AG, Hakonarson H, Milliner DS, Harris PC. Estimated Prevalence of Primary Hyperoxaluria Using Public Whole-Exome Sequencing Datasets. 11th International Primary Hyperoxaluria Workshop. 2014.

9. **Hopp K**, Koon SJ, Heyer CM, Torres VE, Harris PC. Enhanced diagnostics and gene discovery in ARPKD-like and Meckel syndrome (MKS) pedigrees using a next generation sequencing (NGS) ciliopathy panel. [Abstract]. J Am Soc Nephrol. 2014 25: 90A.
10. Kleczko EK, Marsh KH, Chonchol M, Nemenoff RA, **Hopp K**. Investigating the role of T Cells in ADPKD progression [Abstract]. J Am Soc Nephrol. 2016 27: 84A
11. Olson RJ, **Hopp K**, Gainullin VG, Harris PC. Transcriptome analysis places primary cilium assembly at the intersection of the Pkhd1-Pkd1. FASEB 2017
12. Montford JR, Bauer CD, Dobrinskikh E, **Hopp K**, Levi M, Nemenoff RA, Furgeson SB. 5-Lipoxygenase Promotes Renal Interstitial Injury and Fibrosis [Abstract]. J Am Soc Nephrol. 2017 30.
13. Kleczko EK, Tyler LC, Marsh KH, Clambey ET, Nemenoff RA, **Hopp K**. CD8+ T-cells play an important role in halting cystogenesis and provide a novel target for slowing ADPKD progression. PKD Connect Research Conference. PKD Foundation. 2018
14. Olson RJ, **Hopp K**, Furtado J, Harris PC. Pkhd1-Pkd1 interact in a dose-dependent manner to exacerbate a dysregulated ciliary compartment. PKD Connect Research Conference. PKD Foundation. 2018
15. Tyler LC, Kleczko EK, Marsh KH, Wallace DP, Chonchol M, Gitomer BY, Nemenoff RA, **Hopp K**. CD8+ T-cells regulate progression of Autosomal Dominate Polycystic Kidney Disease [Abstract]. J Am Soc Nephrol. 2018 29: 30
16. **Hopp K**, Yoder BK, Mrug M, Zimmerman K. Single cell RNA sequencing provides insights into the mechanism through which adaptive immune cells promote injury induced cyst formation. [Abstract]. J Am Soc Nephrol. 2020 31:37

Competitive Poster Abstracts

1. **Hopp K**, Marvin J, Maillet C. Disruption of copper oxidation in Escherichia coli by site directed mutagenesis of CUEO. National Conference on Undergraduate Research (NCUR). 2007.
2. **Hopp K**, Marvin J, Rossetti S, Harris PC. Analysis of atypical splicing in the ADPKD genes. National Conference on Undergraduate Research (NCUR). 2008.
3. Heyer CM, Ars E, **Hopp K**, Rossetti S, Sundsbak JL, Torres VE, Roman E, Zamora I, Torra R, Harris PC. Incompletely penetrant PKD1 alleles mimic ARPKD [Abstract]. J Am Soc Nephrol. 2009 20: 494A.
4. **Hopp K**, Ward CJ, Rossetti S, Heyer CM, Consugar MB, Torres VE, Harris PC. Analysis of incompletely penetrant alleles as phenotypic modifiers of autosomal dominant polycystic kidney disease. Mayo Clinic Young Investigators Symposium. 2010.
5. **Hopp K**, Heyer CM, Henke SA, Sundsbak JL, Torres VE, Rossetti S, Harris PC. Characterization of the genetic complexity of Meckel Syndrome (MKS) using targeted exon-enriched next-Generation sequencing [Abstract]. J Am Soc Nephrol. 2010 21: 673A.
6. **Hopp K**, Ward CJ, Rossetti S, Hommerding CJ, Torres VE, Harris PC. The Pkd1 hypomorphic allele, R3277C, modifies the Pkd1+/- phenotype to early onset disease, suggesting a dose dependent pathogenesis of ADPKD [Abstract]. J Am Soc Nephrol. 2010 21: 525A.

7. Gainullin VG, Hommerding CJ, Tuan H, Fuller JR, **Hopp K**, Ward CJ, Harris PC. Analysis of glycosylation and localization of Polycystin-1. FASEB – Polycystic Kidney Disease: From Bench to Bedside. 2011.
8. Heyer CM, Rossetti S, **Hopp K**, Sundsbak JL, Torres VE, Harris PC. Autosomal dominant polycystic kidney disease (ADPKD) presentation is often influenced by PKD1 hypomorphic alleles [Abstract]. J Am Soc Nephrol. 2011 22: 304A.
9. **Hopp K**, Rossetti S, Ward CJ, Heyer CM, Sundsbak JL, Torres VE, Harris PC. PKD1 hypomorphic alleles act as major modulators of disease severity in autosomal dominant polycystic kidney disease (ADPKD) International Congress of Human Genetics. 2011: PO W1154.
10. Paul B, Sundsbak JL, **Hopp K**, Torres VE, Harris PC. Co-inheritance of a pathogenic mutation and an incompletely penetrant allele in an early onset case of autosomal dominant polycystic kidney disease. Mayo Clinic Young Investigator Research Symposium. 2012.
11. Gainullin VG, **Hopp K**, Hommerding CJ, Ward CJ, Harris PC. Analysis of glycosylation and localization of Polycystin-1. Mayo Clinic Young Investigator Research Symposium. 2012.
12. Chen C, **Hopp K**, Ward CJ, Hogan M, Harris PC. Aberrant microRNA expression patterns in multiple models of autosomal dominant polycystic kidney disease. Mayo Clinic Young Investigator Research Symposium. 2012.
13. **Hopp K**, Rossetti S, Ward CJ, Heyer CM, Sundsbak JL, Torres VE, Harris PC. Inheritance of PKD1 hypomorphic alleles suggests a dosage dependent pathomechanism in autosomal dominant polycystic kidney disease (ADPKD). Mayo Clinic Young Investigator Research Symposium. 2012.
14. Rossetti S, Irazabal MV, **Hopp K**, Kubly VJ, Sundsbak JL, Hogan MC, Harris PC, Torres VE. Analysis of the genomic profile associated with the development of a vascular phenotype in autosomal dominant polycystic kidney disease (ADPKD) using RainDance exon-capture and Illumina next-generation sequencing. Mayo Individualized Medicine Conference. 2012: PO 21
15. **Hopp K**, Heyer CM, Sundsbak JL, Koon SJ, Kubly VJ, Rossetti S, Torres VE, Harris PC. Development and evaluation of exon-enrichment technologies for diagnostic testing of Meckel syndrome (MKS). Mayo Individualized Medicine Conference. 2012: PO 45
16. Chen CY, Ward CJ, **Hopp K**, Harris PC, Hogan MC. Systematic analysis of microRNAs in urinary exosome-like vesicles and correlation with autosomal dominant polycystic kidney disease (ADPKD) [Abstract]. J Am Soc Nephrol. 2012 23: 246A.
17. Rossetti S, Irazabal MV, **Hopp K**, Kubly VJ, Sundsbak JL, Hogan MC, Torres VE, Harris PC. Analysis of the genomic profile associated with the development of a vascular phenotype in autosomal dominant polycystic kidney disease [Abstract]. J Am Soc Nephrol. 2012 23: 699A.
18. **Hopp K**, Heyer CM, Sundsbak JL, Koon SJ, Kubly VJ, Torres VE, Harris PC. Next-Generation sequencing of unresolved Meckel Syndrome pedigrees reveals a complex genetic makeup. American Society of Human Genetics. 2012: PO 1909T
19. Paul BM, Sundsbak JL, Heyer CM, **Hopp K**, Harris PC. Elucidating the disease mechanism in early onset cases of autosomal dominant polycystic kidney disease (ADPKD). Mayo Individualized Medicine Conference. 2013: PO 84.

20. **Hopp K**, Rossetti S, Irazabal MV, Paul BM, Sundsbak JL, Heyer CM, Torres VE, Harris PC. Mild, mutation negative autosomal dominant polycystic kidney disease patients can be explained by mosaicism. Mayo Individualized Medicine Conference. 2013: PO 56.
21. Paul BM, Sundsbak JL, Heyer CM, **Hopp K**, Irazabal MV, Hogan MC, Kubly VJ, Torres VE, Harris PC. In vitro and family analysis to assess the significance of indeterminate PKD1 variants [Abstract]. J Am Soc Nephrol. 2013 24: 694A.
22. Wang X, Ye H, **Hopp K**, Harris PC, Torres VE. COX-2 inhibition in the PCK rat [Abstract]. J Am Soc Nephrol. 2013 24: 392A.
23. Cogal CA, **Hopp K**, Bergstralh EJ, Seide BM, Olson JB, Meek AM, Milliner DS, Harris PC. Phenotype-genotype correlations in primary hyperoxaluria [Abstract]. J Am Soc Nephrol. 2013 24: 530A.
24. **Hopp K**, Cogal AG, Hakonarson H, Milliner DS, Harris PC. Estimated incidence of primary hyperoxaluria using population allele frequencies of disease variants [Abstract]. J Am Soc Nephrol. 2013 24: 529A.
25. **Hopp K**, Wang X, Ye H, Hommerding CJ, Harris PC, Torres VE. Combination therapy with tolvaptan and pasireotide has enhanced efficacy in the Pkd1 R3277C model [Abstract]. J Am Soc Nephrol. 2013 24: 393A.
26. Gainullin VG, Ward CJ, Hommerding CJ, **Hopp K**, Harris PC. PC1-PC2 complex assembly across ER-Plasma Membrane junctions is disrupted in ADPKD. American Society of Cell Biology Annual Meeting. 2013. Poster Presentation ID:827.
27. Gainullin VG, Ward CJ, **Hopp K**, Davies BA, Hommerding CJ, Harris PC. Generation of a knock-in, tagged mouse model of Pkd1 and analysis of PC1 processing and secretion. American Society of Cell Biology Annual Meeting. 2013. Poster Presentation ID:2003.
28. Vargas DM, Warner GM, Nin V, **Hopp K**, Harris PC, Torres VE, Chini EN. Is there a role for caloric restriction in the prevention and treatment of polycystic kidney disease? Mayo Clinic Young Investigator Research Symposium. 2014.
29. Paul BM, **Hopp K**, Sundsbak JL, Heyer CM, Torres VE, Harris PC. Characterization of Autosomal Dominant Polycystic Kidney Disease families using whole exome sequencing. American Society of Human Genetics Annual Meeting. 2014. Poster ID: 2970T.
30. Singh P, Hasadsri L, Mehta R, Cogal AG, **Hopp K**, Harris PC, Lieske JC, Milliner DS. Clinical and biochemical features in Primary Hyperoxaluria Type 3. [Abstract]. J Am Soc Nephrol. 2014 25: 178A.
31. Heyer CM, Sundsbak JL, Braun W, Chapman AB, Perrone RD, Schrier RW, Steinman TI, Torres VE, Bae KT, Moore CG, Flessner MF, **Hopp K**, Harris PC, HALT PKD Study. Complex genotypes identified through genetic characterization of the HALT PKD ADPKD cohort. [Abstract]. J Am Soc Nephrol. 2014 25: 769A.
32. Irazabal MV, Kline TL, Ebrahimi B, **Hopp K**, Macura S, Lerman LO, Harris PC, King BF, Torres VE, Erickson BJ. Functional magnetic resonance imaging to assess disease severity in Autosomal Dominant Polycystic Kidney Disease (ADPKD). [Abstract]. J Am Soc Nephrol. 2014 25: 404A.

33. Kline TL, Irazabal MV, Ebrahimi B, **Hopp K**, Warner JD, Udoji KN, Lerman LO, Harris PC, King BF, Torres VE, Erickson BJ. Magnetization transfer imaging for tissue remodeling analysis in a murine model of ADPKD. [Abstract]. J Am Soc Nephrol. 2014 25: 91A.
34. **Hopp K**, Wang X, Ye H, Irazabal MV, Harris PC, Torres VE. Effects of hydration in rodent models of Polycystic Kidney Disease: Differences between rats and mice. [Abstract]. J Am Soc Nephrol. 2014 25: 404A.
35. **Hopp K**, Koon SJ, Heyer CM, Torres VE, Harris PC. Utilizing next-generation sequencing to resolve the etiology of ciliopathy pedigrees. Mayo Research Fellows' Day. 2014.
36. Escobar DL, **Hopp K**, Sieben CJ, Harris PC. Genetic background radically alters disease progression in the Pkd1RC/RC model [Abstract]. J Am Soc Nephrol. 2015 26: 835A.
37. **Hopp K**, Koon SJ, Heyer CM, Torres VE, Harris PC. Whole Exome Sequencing (WES) Resolves ARPKD-like and Meckel Syndrome (MKS)-like Pedigrees Unresolved by Sanger/Ciliopathy Panel Screening [Abstract]. J Am Soc Nephrol. 2015 26: 139A.
38. Ravichandran K, **Hopp K**, Thorburn A, Edelstein CL. Suppressed Autophagy Leads to Increased Apoptosis in Pkd1 Knockout Models [Abstract]. J Am Soc Nephrol. 2016 27: 487A
39. Olson RJ, **Hopp K**, Gainullin VG, Harris PC. Developing a mouse model better reflecting ARPKD renal disease severity [Abstract]. J Am Soc Nephrol. 2016 27: 483A
40. Nemenoff RA, Marsh KH, Kleczko EK, Chonchol M, Hopp K. In Vivo Functional Genomics Screen to Identify Genetic Disease Modifier Driving Autosomal Dominant Polycystic Kidney Disease Phenotypic Heterogeneity [Abstract]. J Am Soc Nephrol. 2016 27: 769A
41. Gitomer BY, Wang W, Nowak KL, **Hopp K**, You Z, Brosnahan GM, Harris PC, Torres VE, Chapman AB, Perrone RD, Steinman TI, Yu AS, Abebe KZ, Bae KT, Chonchol M. Circulating Interleukin-6 Level Predicts Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease [Abstract]. J Am Soc Nephrol. 2017 481.
42. Kleczko EK, Marsh KH, Clambey ET, Furgeson SB, Gitomer BY, Chonchol M, Nemenoff RA, **Hopp K**. Activation of CD8+ T-Cells Inhibits Cyst Growth in a Murine Model of ADPKD [Abstract]. J Am Soc Nephrol. 2017 247.
43. Wang W, Tan AC, Kim J, Chonchol M, You Z, **Hopp K**, Nowak KL, Brosnahan GM, Harris PC, Torres VE, Chapman AB, Perrone RD, Steinman TI, Yu AS, Abebe K, Bae KT, Gitomer BY. Serum micro RNA levels and disease progression in ADPKD. [Abstract]. J Am Soc Nephrol. 2018 29:867.
44. Gitomer BY, You Z, Wang W, **Hopp K**, Brosnahan GM, Nowak KL, Harris PC, Torres VE, Chapman AB, Perrone RD, Steinman TI, Yu AS, Bae KT, Abebe K, Chonchol M. Nephrolithiasis as a Risk factor for Kidney Disease Progression in ADPKD. [Abstract]. J Am Soc Nephrol. 2018 29:867.
45. Gitomer BY, Pereira RC, Salusky IB, Wang W, **Hopp K**, Jovanovich AJ, You Z, Nowak KL, Chonchol M. The effect of PKD gene mutations on Bone. [Abstract]. J Am Soc Nephrol. 2019 30:252.
46. Schaefer M, Bjornstad P, Bispham N, You Z, Nowak KL, **Hopp K**, Brosnahan GM, Chonchol M, Gitomer BY. Peak renal blood flow rate correlates with renal function in adults with ADPKD. Abstract]. J Am Soc Nephrol. 2019 30:341.

47. Wang W, Klawitter J, You Z, Nowak KL, **Hopp K**, Brosnahan GM, Chonchol M, Gitomer BY. Global DNA hypomethylation in Autosomal Dominant Polycystic Kidney Disease. [Abstract]. J Am Soc Nephrol. 2019 30:632.
48. Nguyen D, Kleczko EK, Gitomer BY, Clambey ET, Chonchol M, Klawitter J, Nemenoff RA, **Hopp K**. Targeting immunosuppressive pathways reduces ADPKD progression in a relevant murine model. [Abstract]. J Am Soc Nephrol. 2019 30:882.
49. Holditch SJ, Brown CN, Atwood D, **Hopp K**, Edelstein CL. The consequences of decreased cap-dependent translation in Polycystic Kidney Disease. [Abstract]. J Am Soc Nephrol. 2019 30:883.
50. Atwood D, Pokhrel D, Brown CM, Hopp K, Edelstein C. The Effect of Trehalose on Autophagy-Related Proteins and Cyst Growth in a Hypomorphic Pkd1 Mouse Model of Autosomal Dominant Polycystic Kidney Disease (ADPKD). [Abstract]. J Am Soc Nephrol. 2020 31: 494.
51. Atwood D, Brown CN, Hopp K, Edelstein C. Suppressed Autophagic Flux in the Heart in a Hypomorphic Pkd1 Mouse Model of ADPKD. [Abstract]. J Am Soc Nephrol. 2020 31: 494.